Neuromodulation in Depressed and Schizophrenic Patients - Changing MEP (Muscle Evoked Potentials) by tDCS (Transcranial Direct Current Stimulation)

Transcranial Direct Current Stimulation (tDCS)-Boosted Changes in Muscle Evoked Potentials (MEP) in Depressed and Schizophrenic Patients Reveal Deficits in Neuromodulation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01150734

Enrollment

Registered

2010-06-25

Start date

2009-10-31

Completion date

2011-01-31

Last updated

2011-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Schizophrenia

Keywords

differences of Muscle evoked potentials (MEP) in psychiatric illnesses, differences in neuromodulation, normalization of neuromodulation after pharmacological treatment

Brief summary

Muscle evoked potentials (MEP) are supposed to different in schizophrenic and depressed patients, compared to a sample of healthy volunteers. Transcranial Magnetic Stimulation (TMS)-evoked MEP are measured in all three groups at baseline and after tDCS (2 mA, 20 minutes). MEP amplitudes are supposed to normalize quickly in healthy volunteers, to stay diminished in depressed patients and to stay elevated in schizophrenic patients. These differences should disappear after regular pharmacological treatment. Outcome measures will be done in week 2 and week 4.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* The patient must be in the condition to understand the patient-information, as well as the necessary examinations. * He/she must be able to give a written consent. * No medication at least three weeks before enrollment.

Exclusion criteria

* Existence of a care/legal incapacity * Existing pregnancy * Severe psychiatric illness (with exception of affective disorder) * Acute suicidality * Drug-, medication- or alcohol dependence * Dementia according to DSM IV / ICD 10-criterions * Severe brain infarctus in the anamnesis * Indications of structural damage of the basal ganglia or the brain stem * Severe neurological disorders (e.g. M. Parkinson, epilepsy, discus-prolapse, dementia, systemic neurological illnesses, normal pressure hydrocephalus, cerebrovascular diseases, elevated intracranial pressure, in the last 6 months, polyneuropathies). * Severe other medical conditions, like manifest arterial hypertonia, severe heart disease, pacemakers, respiratory failure, malignant illnesses all type, also in the history, active infectious diseases, skeletal disorders (like M. Paget, osteoporosis with spontaneous fractures, fresh fractures) Other circumstances, that speaks against a participation of the patient pinion of Medical Doctor at this study.

Design outcomes

Primary

Measure	Time frame	Description
Decreased MEP amplitudes in depressed patients	at baseline	MEP amplitudes are supposed to be lower than in healthy controls or schizophrenic patients

Secondary

Measure	Time frame	Description
Elevated MEP amplitudes in schizophrenic patients	at baseline	MEP amplitued are supposed to be elevated in schizophrenic patients in comparison to depressed patients or healthy controls
Normalization of MEP amplitudes after drug treatment	4 weeks after baseline	MEP aplitued of schizophrenic patients are supposed to normalize after regular drug treatment within 4 weeks.

Countries

Germany

Outcome results